NCT06378047 is a Phase 1 clinical trial of Pembrolizumab in Pancreatic Cancer, sponsored by H. Lee Moffitt Cancer Center and Research Institute.

Who is sponsoring NCT06378047?

NCT06378047 is sponsored by H. Lee Moffitt Cancer Center and Research Institute.

What drugs are being tested in NCT06378047?

Interventions in NCT06378047: Pembrolizumab, Irreversible Electroporation.

What condition does NCT06378047 study?

NCT06378047 studies Pancreatic Cancer, Locally Advanced Pancreatic Cancer.

Is NCT06378047 still recruiting?

NCT06378047 is currently completed. Last updated 9 February 2026.

Last reviewed 2026-02-09 · How we verify

NCT06378047

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer

Completed Phase 1 Last updated 9 February 2026

What this trial tests

Phase 1 trial testing Pembrolizumab in Pancreatic Cancer in 2 participants. Completed in 15 September 2025.

Timeline

10 April 2024

Primary endpoint
15 September 2025

15 September 2025

Quick facts

Lead sponsor	H. Lee Moffitt Cancer Center and Research Institute
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	2
Start date	10 April 2024
Primary completion	15 September 2025
Estimated completion	15 September 2025
Sites	1 location across United States

Drugs / interventions tested

Pembrolizumab (pembrolizumab) — full drug profile →
Irreversible Electroporation

Conditions studied

Pancreatic Cancer — all drugs for Pancreatic Cancer →
Locally Advanced Pancreatic Cancer — all drugs for Locally Advanced Pancreatic Cancer →

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Who can join

18 and older, any sex, with Pancreatic Cancer or Locally Advanced Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to determine the safety and tolerability of combining sequential therapy of Irreversible Electroporation (IRE) and Immunotherapy (IO) for patients with locally advanced unresectable pancreas cancer following first-line treatment with chemotherapy and ablative stereotactic magnetic resonance image-guided adaptive radiation therapy (A-SMART).

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Recent Advances and Challenges in the Treatment of Advanced Pancreatic Cancer: An Update on Completed and Ongoing Clinical Trials.
Shenoy A, Yousif A, Hussain MD. · · 2025 · cited 3× · PMID 40282495 · DOI 10.3390/cancers17081319
High-voltage electrical pulses for pancreatic cancer treatment in the era of precision medicine.
Ma W, Liu H, Xu F, Xu L, et al · · 2026 · cited 1× · PMID 40923270 · DOI 10.1097/js9.0000000000003386
Inflammation, Immunosuppression, and Immunotherapy in Pancreatic Cancer-Where Are We Now?
Fudalej M, Krupa K, Badowska-Kozakiewicz A, Deptała A. · · 2025 · cited 1× · PMID 40361411 · DOI 10.3390/cancers17091484
Threading the Needle: Navigating Novel Immunotherapeutics in Pancreatic Ductal Adenocarcinoma.
Demir T, Moloney C, Mahalingam D. · · 2025 · cited 1× · PMID 40075563 · DOI 10.3390/cancers17050715
Pulsed electric fields: a sharp sword in the battle against cancers.
Zhang L, Dong S, Teng F, Wang Y, et al · · 2025 · PMID 41357174 · DOI 10.3389/fimmu.2025.1682539
Irreversible electroporation with intratumoral plant virus immunotherapy induces systemic immunity in a metastatic model of pancreatic cancer.
Ledezma DK, Joshi U, Nguyen-Ta K, Sonowal H, et al · · 2025 · PMID 41045984 · DOI 10.1016/j.canlet.2025.218074
Interventional oncology and immunotherapy: current status and future perspectives.
Ma J, Wei Z, Ye X. · · 2025 · PMID 40264767 · DOI 10.3389/fimmu.2025.1541105

Verify or expand the search:

Other trials of Pembrolizumab

Trials testing the same drug.

NCT07572123 — Evaluating the Addition of Maintenance Immunotherapy Compared to the Usual Treatment of Chemotherapy and Autologous Stem · Phase 2, PHASE3 · not yet recruiting
NCT07275216 — Pembrolizumab in Combination With Chemotherapy for the Treatment of Frail Hodgkin Lymphoma Patients Ineligible for Stand · Phase 2 · not yet recruiting
NCT07302347 — A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participan · Phase 1, PHASE2 · recruiting
NCT06724042 — Study of ISM5939 in Patients With Advanced and/or Metastatic Solid Tumors · Phase 1 · not yet recruiting
NCT07383441 — Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer · Phase 3 · not yet recruiting

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting

Other H. Lee Moffitt Cancer Center and Research Institute trials

Trials by the same sponsor.

NCT05041335 — Wet Heparinized Suction for Abdominal Cancer · NA · not yet recruiting
NCT07222995 — Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs · NA · recruiting
NCT06047977 — Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors · Phase 1 · recruiting
NCT06121180 — Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma · Phase 2 · recruiting
NCT06193486 — Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06378047 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by H. Lee Moffitt Cancer Center and Research Institute
Last refreshed: 9 February 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06378047.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing